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Background: Raised levels of pro-inflammatory, pro-resorptive cytokines during pulmonary infection may contribute to osteoporosis in cystic
fibrosis (CF). We assessed osteoclast number and activity during infective exacerbations and examined their relationship to serum inflammatory
cytokines and bone turnover markers.
Methods: Serum samples from 24 adults with CF were obtained before, during and after treatment of infection. Osteoclastic cells were generated
from peripheral blood mononuclear cells and their number and activity assessed. Serum osteocalcin, type 1 collagen cross-linked N-telopeptide
(NTx), interleukin-6 (IL-6), tumour necrosis factor alpha (TNFα), receptor activator of NFkB ligand (RANKL) and osteoprotegerin (OPG) were
measured.
Results: Osteoclast number and activity were increased at the start of exacerbation and decreased with antibiotic therapy. Significant correlations
were demonstrated between osteoclast formation and serum TNFα, OPG, osteocalcin and NTx and between osteoclast activity and serum IL-6 and
NTx.
Conclusions: The systemic response to infection is associated with increased bone resorptive activity in patients with CF.
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Cystic fibrosis (CF) is associated with reduced bone mineral
density (BMD) and increased risk of fracture [1–4]. The aetiology
is multifactorial and includes vitamin D insufficiency, malnutri-
tion, glucocorticoid use, reduced levels of physical activity and
hypogonadism [5]. However, the most consistent correlate of low
bone mass is the severity of disease, as defined by lung function
and nutritional parameters [6]. The mechanism of this associa-
tion remains only partially identified, but may relate to effects
of the systemic inflammatory response to pulmonary infection
on osteoclast function and formation [7–9]. Thus many of the
cytokines released during infection also have stimulatory effects
on osteoclast development and activity, resulting in increased⁎ Corresponding author.
1569-1993/$ - see front matter © 2009 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2009.11.007bone resorption; these include interleukin-6 (IL-6), tumour
necrosis factor alpha (TNFα) and receptor activator of NFkB
ligand (RANKL) [10–12]. Inflammation and associated altera-
tions in cytokine levels have been implicated in the pathogenesis
of bone loss in postmenopausal osteoporosis [13], rheumatoid
arthritis [14–16], Paget's disease of bone, multiplemyeloma [17],
periodontitis [18] and inflammatory bowel disease [19,20].
In patients with CF, increased production of a range of pro-
inflammatory, pro-resorptive cytokines has been reported during
infective exacerbations and, in some studies, BMD or rates of
bone loss have been shown to correlate with circulating levels of
these cytokines [21–23]. Based on the hypothesis that bone
resorption is increased during infection as a result of increased
cytokine production, we studied osteoclast number and activity
during infective exacerbations in patients with CF and investi-
gated their relationship to changes in serum cytokine levels and
biochemical markers of bone formation and resorption.d by Elsevier B.V. All rights reserved.
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2.1. Patients
Patients were recruited from Papworth Adult Cystic Fibrosis
Centre, UK using the following inclusion criteria: CF confirmed
by gene analysis or abnormal sweat test, age ≥18 years, forced
expiratory volume in 1s (FEV1) b75% predicted, at least one
course of intravenous (IV) antibiotic therapy for respiratory
exacerbation in the preceding year and primarily infected with
Pseudomonas aeruginosa. Patients were excluded if they had
received oral glucocorticoids in the 3 months prior to recruitment
or during the study period, had received bisphosphonates, were
pregnant during the study period, had renal dysfunction (elevated
serum urea and/or creatinine) or if they were post-transplantation.
Six healthy controls were recruited (3 male, 3 female) from
laboratory staff with a mean age of 23.3 [1.2] years. The study
was approved by the Local Research Ethics Committee and
informed written consent was obtained from all patients and
controls.
In 9 patients peripheral blood samples were taken at baseline
(clinically stable, defined as no exacerbation requiring treatment
for ≥1 month), day 1 (start of exacerbation prior to intravenous
antibiotic therapy, exacerbation defined by Fuchs criteria [24]),
day 14 (end of intravenous antibiotic therapy and patients
clinically stable with clinical evidence of resolution) and day 42
(follow-up clinic appointment). However, due to an insufficient
number of patients experiencing exacerbations after baseline
samples had been taken, the protocol was changed so that blood
samples in the subsequent 15 patients were taken at just three
time points during exacerbation: day 1, day 14 and day 42 as
defined above. All 24 patients had exacerbation during the
study period and in all cases were clinically stable at day 42.
Clinical evaluation of infective status before, during and after
treatment was performed by a senior clinician (CSH or DB),
based on clinical examination, lung function tests and blood
tests. For practical reasons it was not possible to obtain fasting
samples, although most samples were obtained during the
morning.
2.2. Serum separation
Peripheral blood was collected into serum-gel monovettes
(Sarstedt, UK), mixed well and allowed to clot. Serum was
frozen at −80 °C within 2 h of separation.
2.3. Osteoclast generation
Peripheral blood mononuclear cells were plated at
3.0×105 cells/ml on to Osteologic™ slides (BD Biosciences,
UK) or 96-well plates and cultured in α-Minimal Essential
Medium (MEM) containing RANKL (50 ng/ml) (Insight
Biotechnology) and macrophage-colony stimulating factor
(25 ng/ml) (RnD Systems). Cultures were incubated at 37 °C
in 5% CO2-air for up to 10 days (Osteologic™ slides) or 14 days
(plastic) before analysis of osteoclast formation and resorption
[25]. The number of osteoclastic cells was assessed using atartrate-resistant acid phosphatase (TRAP) stain, which is specific
for osteoclastic cells. Positive staining cells were quantitatively
assessed by microscopy. Osteoclast activity was assessed by
measurement of the area resorbed on Osteologic™ slides [25].
The total area resorbed was quantified using image capture
software or Adobe® Photoshop® (Adobe systems, Inc.) to
calculate total area resorbed as a percentage of total area.2.4. Enzyme linked immunosorbant assays (ELISA assays)
ELISA kits used were IL-6 (900-K16), TNFα (900-K25),
sRANKL (900-K142) from Peprotech Ltd. (Europe) and OPG
(DY805) from R&D systems. Serum osteocalcin was measured
using the Biosource (France) human osteocalcin (KAP1381)
ELISA. Serum type-I collagen cross-linked N-telopeptide
(NTx) was measured using the Osteomark (Unipath Ltd., UK)
competitive inhibition human NTx (9021) ELISA. Intra- and
inter-assay variability were calculated using standards and in-
house controls and, expressed as coefficients of variation, were
4.3% and 5.8% for IL-6, 6.1% and 8.8% for sRANKL, 8.1%
and 3.4% for OPG, and 9.3% and 10.1% for TNFα. The intra-
assay variation for osteocalcin and NTx was 3.5% and 4.9%
respectively.2.5. Statistical analysis
An ANOVA was performed as a global assay to detect
variance over the time course of an exacerbation. A non-paired
Tukey's multiple comparison test was used to compare the
baseline measurements obtained in 9 patients with normal
controls and to examine changes over the time course of the
study in all 24 patients. Correlation analysis was performed using
a two-tailed non-parametric Spearman's rank test with paired data
points. All graphs box and whisker plots show the median and
interquartile range (IQR). For all tests pb0.05 was considered
significant.3. Results
3.1. Patient demographics
24 patients (14 male, 10 female) were recruited with a mean
age [SD] of 27.0 [6.0]years. All had pancreatic insufficiency. 22
were F508 del homozygous, one F508 del/Q220X and one
G551D/unknown.Mean values [SD] at recruitment for FEV1 and
BMI were 46.7% [15.4] and 21.1 [3.2]kg/m2, respectively.
Demographic data in the 9 patients with true baseline samples
were not significantly different from those in the remaining 15
patients. For the 9 patients that had baseline samples, the mean
(SD) number of days between these baseline samples being taken
and day 1 of their next exacerbation was 162 (157)days. For the
15 patients without baseline samples, the mean (SD) number of
days between their day 1 exacerbation sample and their last
exacerbation was 125 (122) days.
95E.F. Shead et al. / Journal of Cystic Fibrosis 9 (2010) 93–983.2. Osteoclast formation and bone resorption
No significant difference was seen in the number of TRAP
positive cells formed in controls (median 39.1, IQR 45.1–54.6)
and CF patients at baseline (median 29.6, IQR 37.0–53.8). Over
the course of an infective exacerbation there was a significant
variation in the number of TRAP positive cells formed in culture
(p=0.013; Fig. 1A).A significant increase in the number of TRAP
positive cells was seen at day 1 of exacerbation (median 48.3, IQR
52.8–59.1) and day 14 (median 52.9, IQR 48.9–58.8) compared
to baseline (pb0.05). A significant decrease was seen by day 42
(median 44.3, IQR 39.4–48.6) compared with the day 1 and day
14 values, to a level comparable to baseline (pb0.05) and normal
controls.
No significant difference was seen between resorption area in
CF patients at baseline (median 7.9%, IQR 6.9–11.8) and normal
controls (median 6.8%, IQR 4.7–9.4). Over the course of an
infective exacerbation there was a significant variation in the
resorption area (expressed as a%of total area) (p=0.005; Fig. 1B).
A significant increase in resorption areawas seen at day 1 (median
12.9%, IQR 11.6–17.0) and day 14 (median 12.0%, IQR 7.4–
15.4) compared to baseline (pb0.05). Levels of resorption at day
42 were comparable to baseline and normal controls.3.3. Serum markers of bone turnover
Serum osteocalcin levels in CF patients at baseline (median
7.3 ng/ml, IQR 3.9–11.9) were significantly lower than those
seen in normal controls (median 12.5 ng/ml, IQR 9.3–16.9;Fig. 1. Variations in osteoclast formation and activity during an infective
exacerbation. (A) Formation of TRAP positive cells and (B) resorption activity
both increased at day 1 and day 14 compared to baseline (*pb0.05).pb0.05). No significant variation in osteocalcin levels was
seen over the time course of an infective exacerbation (Fig. 2A).
Levels of NTx in CF patients at baseline (median 375.0
BCE/l, IQR 322.4–424.5) were not significantly different to
those seen in normal controls (median 373.7 BCE/l, IQR
296.3–469.0). Significant variation in serum levels of NTx was
of an seen over the time course of an infective exacerbation
(p=0.027; Fig. 2B). A significant increase in NTx levels
compared to baseline was seen at day 14 (median 613.2 BCE/l,
IQR 476.8–691.4, pb0.05). By day 42 levels of NTx had
decreased (median 512.5 BCE/l, IQR 393.1–697.7), although
had not returned to baseline.
3.4. Serum cytokine levels
Serum levels of sRANKL in CF patients at baseline (median
39.9 pg/ml, IQR 16.3–48.2) did not differ significantly from
levels in normal controls (median 38.7 pg/ml, IQR 19.3–49.1).
The median level at day 1 was 36.9 pg/ml (IQR 816.4–2683).
Significant variation in serum levels of sRANKL was seen over
the time course of an infective exacerbation (p=0.05) with
significantly increased levels at day 14 (median 132.9 pg/ml,
IQR 37.6–729.1, pb0.05) compared to baseline. Serum levels
decreased by day 42 (median 48.4 pg/ml, IQR 18.3–63.5) to a
level comparable to baseline and normal controls.
Serum levels of OPG in CF patients at baseline (median
1664 pg/ml, IQR 1545–1740) were significantly lower than
those in normal controls (median 2494 pg/ml, IQR 1805–3066,
pb0.05). At day 1 the median level was 1560 pg/ml (IQR 8.7–
317.8). Significant variation in serum levels of OPG was seenFig. 2. Variations in markers of bone metabolism during infective exacerbation.
(A) Serum levels of osteocalcin at baseline were significantly lower than normal
control levels. (B) Serum levels of NTx were significantly increased at day 14
compared to baseline (*pb0.05).
Fig. 3. Correlations between osteoclast formation and activity and markers of
bone metabolism during infective exacerbation. (A) Formation of TRAP
positive cells and resorption activity (pb0.05) and (B) serum levels of NTx and
resorption activity (pb0.01) were significantly correlated during infective
exacerbation.
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significant increase at day 14 (median 2207 pg/ml, IQR 1869–
2895, pb0.05) compared to baseline. The level had decreased
by day 42 (median 1739 pg/ml, IQR 1486–1994, pb0.05) to a
level comparable to baseline.
Serum levels of IL-6 in CF patients at baseline (median
456.0 pg/ml, IQR 233.0–891.9) were significantly higher than
levels in the controls (median 115.0 pg/ml, IQR 95.2–199.7).
Significant variation in serum levels of IL-6 was seen over the
time course of infective exacerbation (p=0.005) with a
significant increase at day 1 (median 756.0 pg/ml, IQR
175.2–1253.0) compared to baseline. A decrease in levels
compared to baseline was seen by day 14 (median 125.0 pg/ml,
IQR 68.1–195.0, pb0.05) and day 42 (median 56.0 pg/ml, IQR
33–82.4, pb0.01).
Serum levels of TNFα in CF patients at baseline (median
32.4 pg/ml, IQR 26.7–73.9) did not differ significantly from
levels in normal controls (median 61.9 pg/ml, IQR 53.7–115.8).
The median value at day 1 was 34.7 pg/ml (range 10.3–96.1).
Significant variation in serum levels of TNFα was seen over the
time course of infective exacerbation (p=0.003) with signifi-
cant increases at day 14 (median 113.8 pg/ml, IQR 48.3–137.6)
and day 42 (median 113.0 pg/ml, IQR 82.5–136.3) compared to
baseline.
3.5. Correlation between osteoclast formation, activity and
serum levels of bone turnover markers and cytokines
The number of TRAP positive cells in culture showed
positive correlations with resorption area (r=0.40, p=0.02;
Fig. 3A), serum NTx (r=0.48, p=0.014) and serum TNFα
(r=0.37, p=0.03) and a negative correlation with serum
osteocalcin (r=−0.38, p=0.04) and OPG (r=−0.36, p=0.05).
Positive correlations were also seen between resorption area and
serum NTx (r=0.84, p=0.005; Fig. 3B) and IL-6 (r=0.41,
p=0.02).
4. Discussion
The results of our study add new evidence to support the role
of infection in the pathogenesis of CF-related low BMD. In
particular, our results show evidence of increased production
and activity of osteoclasts during infective exacerbations in
association with increases in circulating levels of pro-resorptive
cytokines and serum NTx, a marker of whole body bone
resorption. These findings extend our previous work showing
an increase in the production of potential osteoclast precursors
in the peripheral blood during CF infective exacerbations [9].
The significant correlations observed in the present study
between serum NTx and both TRAP positive cell production
and resorption area add further evidence to the proposed
association between infection and increased bone resorption.
Our results are broadly consistent with and extend those
reported in two previous studies in adults with CF. In one of
these [8], serum samples were obtained at the start and end of a
2 week course of antibiotics for infective exacerbation. At the
start of therapy, serum levels of NTx, IL-1β and IL-6 wereelevated compared to healthy controls and fell during antibiotic
therapy, although they remained higher than the control values
at the end of the 2 week study period. The values for serum IL-6
and TNFα obtained in our study were higher than those reported
previously, both in patients and controls, although all values
were within the normal range provided by the manufacturer.
Aris et al. [7] studied 17 adults with CF at day 1 of antibiotic
therapy and subsequently on day 18 and day 40. Serum IL-1β,
IL-6 and TNFα values declined during antibiotic therapy and
NTx also decreased, having been elevated above the normal
reference range at day 1. In both of these studies, baseline
samples prior to the infective exacerbation were not obtained. In
contrast, in the present study a number of patients (n=9) had
blood sampling prior to infection, providing a true baseline from
which to demonstrate changes attributable to infective exacer-
bation and allowing for a true ‘non-exacerbating’ comparison to
be made with normal controls. Unfortunately, because of the
low rate of infective exacerbations in patients in whom a
baseline sample had been obtained, it was necessary to change
the protocol and thus true baseline samples were only available
in 9 patients. However, in all patients samples were obtained at
day 42, when there was clinical evidence of resolution of
infection in all cases and most of the measured parameters had
returned to or near baseline values.
Changes in serum levels of RANKL and OPG have not been
previously reported in this patient group. RANKL is a major
regulator of osteoclast production and activity, interacting with
the RANK receptor to stimulate the formation of osteoclasts and
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soluble decoy receptor that binds to RANKL, thereby
preventing it from binding to RANK and inhibiting its pro-
resorptive effect. Levels of serum OPG in baseline samples
from patients with CF were significantly lower when compared
to normal controls whereas serum RANKL levels were similar
in the two groups and day 1 levels were similar to those
obtained at baseline for both cytokines. The low levels of OPG,
in the presence of normal serum RANKL levels may have
contributed to increased osteoclastogenesis and activity at the
beginning of the infective exacerbation. An increase in serum
levels of both cytokines during infective exacerbation was
observed in our study, although this was only statistically
significant for OPG; levels of both cytokines decreased after the
completion of intravenous antibiotic therapy. An increase in
OPG levels has been reported to accompany increased RANKL
production in other situations associated with bone loss and may
represent a compensatory phenomenon aimed at protecting the
skeleton from excessive bone resorption [27].
In the present study baseline values of NTx, a marker of bone
resorption, were similar in CF patients and controls, whilst
baseline serum osteocalcin levels were significantly lower in CF
patients. These findings are consistent with our previous
histomorphometric study in patients with CF, which demon-
strated decreased bone formation as the predominant change,
whilst bone resorption was normal in most patients, although
increased in some [28]. Aris et al. [7] reported higher levels of
urinary NTx and free deoxypyridinoline, both markers of bone
resorption, in clinically stable CF patients when compared to
controls, but similar serum osteocalcin levels. The reasons for
these differences are unclear but may be related to differences in
clinical characteristics of the patient groups, for example disease
activity, glucocorticoid use and/or measurement-related issues
(i.e. serum vs. urinary NTx assays). Taken together, the current
evidence supports a role for both reduced bone formation and
increased bone resorption in the pathophysiology of bone loss
associated with CF, the latter being most conspicuous during
infective exacerbations.
Our study has several limitations. First, the number of
patients studied was relatively small and the statistical power to
demonstrate changes was thus limited and further compromised
by our ability to obtain true baseline blood samples, prior to
infection, in only 9 of the 24 patients. However, demographic
characteristics and changes in cytokine and biochemical marker
levels were similar in the patients with and without true baseline
values. The power of the study to show significant changes may
also have been reduced by differences between patients in the
severity of infective exacerbation and the corresponding effect
of this on the variance of some of the measured indices. The
number of controls studied was also small. Secondly, levels of
IL-6, osteocalcin and NTX, (but not RANKL, OPG or TNFα)
exhibit circadian variations [29,30] and may also be affected by
intake of food; fasting samples taken at the same time of day
would therefore have been optimal. However, for practical
reasons it was not possible to obtain fasting samples in most
patients in this study, although in the majority sampling was
performed in the morning hours. Finally, osteoclastic cellsgenerated from peripheral blood mononuclear cells may not be
fully representative of osteoclasts formed in vivo and peripheral
blood mononuclear cells circulating at the time of infection may
also have the ability to differentiate into dendritic cells or
macrophages.
The demonstration of a direct association between infective
exacerbations in CF and increased bone resorption has potential
clinical implications and suggests that measures taken to reduce
the risk of infection and to treat infective exacerbations promptly
and effectively may improve bone health. Our findings also
provide a rationale for the use of anti-resorptive drugs in the
management of bone disease in patients with CF.
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